Susan Serrao, Author at BioAegis Therapeutics

March 2020: Chief Medical Officer Discusses COVID-19 in KYW InDepth Podcast

Our Chief Medical Officer and infectious disease expert, Dr. Mark DiNubile, was recently interviewed for a KYW InDepth podcast. Highlights of the podcast include: What happens to our lungs when COVID-19 attacks our bodies and why some people end up in the ICU on ventilators. How the naturally-occurring human protein, plasma gelsolin, works in our […]

March 2020: Chief Medical Officer Discusses COVID-19 in KYW InDepth Podcast Read More »

Plasma Gelsolin to Protect Tissue/Organs in Severe Coronavirus Infection without Compromising Pathogen Response

COVID19 / Susan Serrao

SUMMARY SARS-CoV-2 causes fatal infections by eliciting an over-exuberant immune response leading to injurious lung inflammation +/- a cytokine storm. Patients may die from ARDS or survive with debilitating pulmonary fibrosis. Interventions like hydroxychloroquine have been proposed as treatment modalities to modulate the intense host reaction and potentially improve respiratory outcomes despite lack of a

Plasma Gelsolin to Protect Tissue/Organs in Severe Coronavirus Infection without Compromising Pathogen Response Read More »

Gelsolin: A New Biomarker of Disease Activity in SLE Patients Associated with HDL-c

Publication / Susan Serrao

Parra S, Heras M, Herrero P, Amigó N, Garcés E, Girona J, Correig X, Canela N, Castro A. Rheumatology (Oxford). 2020 Mar 1;59(3):650-661. doi: 10.1093/rheumatology/kez293. PMID: 31504936.

Gelsolin: A New Biomarker of Disease Activity in SLE Patients Associated with HDL-c Read More »

February, 2020: BioAegis Commentary Featured on CNBC

News / Susan Serrao

Commentary Steve Cordovano, co-founder of BioAegis Therapeutics Published February 25, 2020 On Tuesday the number of confirmed coronavirus cases worldwide hit 80,370, with more than 2,700 deaths worldwide, raising concerns that the outbreak has reached a new stage and could continue its global spread. But why is it that the health sector is so woefully unprepared

February, 2020: BioAegis Commentary Featured on CNBC Read More »

Howard Levy, M.B.B.Ch., Ph.D., M.M.M.

Leadership / Susan Serrao

Chief Medical Officer

Howard Levy, M.B.B.Ch., Ph.D., M.M.M. Read More »

Large-Scale Multi-Omic Analysis of COVID-19 Severity

Publication / Susan Serrao

Overmyer, Katherine A, et al. MedRxiv, Cold Spring Harbor Laboratory Press, 1 Jan. 2020.

Large-Scale Multi-Omic Analysis of COVID-19 Severity Read More »

Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe Influenza.

Publication / Susan Serrao

Yang, Zhiping, et al. F1000Research, F1000 Research Limited, 6 Nov. 2019.

Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe Influenza. Read More »

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman

News / Susan Serrao

MORRISTOWN, N.J., Oct. 22, 2019 (BIOAEGIS THERAPEUTICS) — BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur. PitchBook is a financial data and software company that provides transparency to capital markets to help professionals discover and execute opportunities. BioAegis Therapeutics’ accolade was based

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman Read More »

Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and Penicillin-Resistant Pneumococcal Pneumonia

Publication / Susan Serrao

Yang, Zhiping, et al. The Journal of Infectious Diseases, Oxford University Press, 26 Sept. 2019.

Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and Penicillin-Resistant Pneumococcal Pneumonia Read More »

Low Admission Plasma Gelsolin Concentrations Identify Community-Acquired Pneumonia Patients at High Risk for Severe Outcomes

Publication / Susan Serrao

Self, Wesley H, et al. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, Oxford University Press, 13 Sept. 2019.

Low Admission Plasma Gelsolin Concentrations Identify Community-Acquired Pneumonia Patients at High Risk for Severe Outcomes Read More »

Susan Serrao

March 2020: Chief Medical Officer Discusses COVID-19 in KYW InDepth Podcast

Plasma Gelsolin to Protect Tissue/Organs in Severe Coronavirus Infection without Compromising Pathogen Response

Gelsolin: A New Biomarker of Disease Activity in SLE Patients Associated with HDL-c

February, 2020: BioAegis Commentary Featured on CNBC

Howard Levy, M.B.B.Ch., Ph.D., M.M.M.

Large-Scale Multi-Omic Analysis of COVID-19 Severity

Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe Influenza.

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman

Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and Penicillin-Resistant Pneumococcal Pneumonia

Low Admission Plasma Gelsolin Concentrations Identify Community-Acquired Pneumonia Patients at High Risk for Severe Outcomes

Recent News

August 20, 2025: BioAegis Therapeutics Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness (DCS)

June 17, 2025: BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

Company Location

Follow Us